共 113 条
[11]
Nathan DM(2011)Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study Eur Heart J 32 1900-1908
[12]
Wright A(2007)A systematic review and meta-analysis of hypoglycemia and cardiovascular events: a comparison of glyburide with other secretagogues and with insulin Diabetes Care 30 389-394
[13]
Burden AC(2008)Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes N Engl J Med 358 2560-2572
[14]
Paisey RB(2011)Resolving drug effects from class effects among drugs for type 2 diabetes mellitus: more support for cardiovascular outcome assessments Eur Heart J 32 1832-1834
[15]
Cull CA(2008)Effects of intensive glucose lowering in type 2 diabetes N Engl J Med 358 2545-2559
[16]
Holman RR(2013)Cause-specific cardiovascular risk associated with nonsteroidal anti-inflammatory drugs among myocardial infarction patients—a nationwide study PLoS One 8 e54309-396
[17]
Pugh JA(2011)The predictive value of ICD-10 diagnostic coding used to assess Charlson comorbidity index conditions in the population-based Danish National Registry of Patients BMC Med Res Methodol 11 83-1705
[18]
Wagner ML(1999)Comparison of bedtime insulin regimens in patients with type 2 diabetes mellitus. A randomized, controlled trial Ann Intern Med 130 389-1693
[19]
Sawyer J(2009)Combining insulin with metformin or an insulin secretagogue in non-obese patients with type 2 diabetes: 12 month, randomised, double blind trial BMJ 339 b4324-610
[20]
Ramirez G(1971)The UGDP study JAMA 218 1704-15